Objective
to report the 3-year clinical outcome of PCI with sirolimus-eluting stent with ultra thin struts (Supraflex) compared with everolimus eluting stent (Xience)
Study
prospective multicentre non-inferiority randomised trial
Population
all-comers
Endpoints
MACE: cardiac death, TV-MI or clinically indicated target lesion revascularisation at 3 years
Conclusion
the 3-year MACE rate of PCI treatment of all-comers with Supraflex stent is not statistically different from PCI with Xience stent
de Winter et al. EuroIntervention. 2022; March